Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Restructuring Reflects Belief That Manufacturing Problems Are In The Past

This article was originally published in The Pink Sheet Daily

Executive Summary

John Lechleiter is elevated to the position of President and Chief Operating Officer effective Oct. 1.

You may also be interested in...



Lilly To Pay Up To $690 Mil. To Settle Majority Of Zyprexa Injury Claims

Settlement will cover approximately 8,000 personal injury claims regarding diabetes and hyperglycemia, or about 75% of the total number of cases, Lilly says. “Lilly is prepared to continue its vigorous defense of Zyprexa in the remaining cases,” the company said.

Lilly Zyprexa Patent Upheld On All Counts

The district court ruling means that generic versions of olanzapine are unlikely to enter the market before 2011, when the only "Orange Book" listed patent for Zyprexa is set to expire.

NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter

DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel